These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Universal Influenza Vaccine Approaches Using Full-Length or Head-Only Hemagglutinin Proteins. Ross TM J Infect Dis; 2019 Apr; 219(Suppl_1):S57-S61. PubMed ID: 30715379 [TBL] [Abstract][Full Text] [Related]
24. Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. Broecker F; Liu STH; Sun W; Krammer F; Simon V; Palese P J Virol; 2018 Oct; 92(20):. PubMed ID: 30045991 [TBL] [Abstract][Full Text] [Related]
25. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk. Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338 [TBL] [Abstract][Full Text] [Related]
26. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655 [TBL] [Abstract][Full Text] [Related]
27. Influenza vaccine: progress in a vaccine that elicits a broad immune response. Isakova-Sivak I; Stepanova E; Mezhenskaya D; Matyushenko V; Prokopenko P; Sychev I; Wong PF; Rudenko L Expert Rev Vaccines; 2021 Sep; 20(9):1097-1112. PubMed ID: 34348561 [TBL] [Abstract][Full Text] [Related]
28. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742 [TBL] [Abstract][Full Text] [Related]
30. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. Langley JM; Frenette L; Ferguson L; Riff D; Sheldon E; Risi G; Johnson C; Li P; Kenney R; Innis B; Fries L J Infect Dis; 2010 Jun; 201(11):1644-53. PubMed ID: 20423222 [TBL] [Abstract][Full Text] [Related]
31. Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. Nachbagauer R; Choi A; Izikson R; Cox MM; Palese P; Krammer F mBio; 2016 Jan; 7(1):e01996-15. PubMed ID: 26787832 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987 [TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus. Di Mario G; Soprana E; Gubinelli F; Panigada M; Facchini M; Fabiani C; Garulli B; Basileo M; Cassone A; Siccardi A; Donatelli I; Castrucci MR Pathog Glob Health; 2017 Mar; 111(2):69-75. PubMed ID: 28081672 [TBL] [Abstract][Full Text] [Related]